CRTKVA11-01 TCR cell thearpy (Corregene)

N/A

Report date: 2026/01/31 20:00:09
First In Class

Base Information

Drug NameCRTKVA11-01 TCR cell thearpy (Corregene)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionKRAS G12V modulators
TargetsKRAS G12V
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCorregene Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCorregene Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A